Gilead Sciences

YTD

ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

CEO

Daniel P. O'Day

CEODaniel P. O'Day

Employees

17,000

Employees17,000

Headquarters

Foster City, California

HeadquartersFoster City, California

Founded

1987

Founded1987

Employees

17,000

Employees17,000

GILD Key Statistics

Market cap

151.50B

Market cap151.50B

Price-Earnings ratio

17.08

Price-Earnings ratio17.08

Dividend yield

2.54%

Dividend yield2.54%

Average volume

9.63M

Average volume9.63M

High today

$126.00

High today$126.00

Low today

$121.58

Low today$121.58

Open price

$124.74

Open price$124.74

Volume

4.86M

Volume4.86M

52 Week high

$157.29

52 Week high$157.29

52 Week low

$104.46

52 Week low$104.46

Stock Snapshot

Gilead Sciences(GILD) stock is priced at $122.03, giving the company a market capitalization of 151.5B. It carries a P/E multiple of 17.08 and pays a dividend yield of 2.5%.

During the trading session on 2026-06-10, Gilead Sciences(GILD) shares reached a daily high of $126.00 and a low of $121.58. At a current price of $122.03, the stock is +0.4% higher than the low and still -3.2% under the high.

Trading activity shows a volume of 4.86M, compared to an average daily volume of 9.63M.

The stock's 52-week range extends from a low of $104.46 to a high of $157.29.

GILD News

Zacks 1h

Can Gilead Sciences HIV Franchise Drive Long-Term Growth? - Zacks Investment Research

...

Benzinga 1d

Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial

While the combo showed a numerical improvement in progression-free survival, it did not reach statistical significance, and investigators said the probability o...

TipRanks 2d

Merck, Gilead announce discontinuation of Phase 3 KEYNOTE-D46/EVOKE-03 study

Merck (MRK) and Gilead Sciences (GILD) announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study investigating Gilead’s Trodelvy in combination wi...

Analyst ratings

81%

of 31 ratings

Buy

80.6%

Hold

19.4%

Sell

More GILD News

Simply Wall St 4d

Gilead Expands Into Autoimmune Orphan Diseases With Ouro Medicines Deal

Gilead Sciences (NasdaqGS:GILD) has closed the acquisition of Ouro Medicines, bringing a clinical-stage BCMAxCD3 T cell engager, gamgertamig, into its pipeline....

TipRanks 5d

Lakefront Biotherapeutics and Gilead Close Ouro Medicines Deal, Anchor Autoimmune Pipeline Around Gamgertamig

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

TipRanks 5d

Gilead announces launch of lenacapavir in South Africa

Gilead (GILD) applauds the leadership of the Government of South Africa and the Global Fund for accelerating access to lenacapavir, a long-acting HIV prevention...

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.